Search

Vision loss during Eylea treatment for AMD

This report investigated patients who lost more than two lines of vision despite periodic injections of aflibercept and explored the factors associated with vision loss. One hundred and ninety-six eyes were included in this study over a two year period....

RTP801 as a neuroprotective and axon regenerative treatment

This paper describes the neuroprotective and axon regenerative effects of siRTP801, which is a translatable small-interfering RNA (siRNA) targeting mTOR negative regulator; RTP801, through in-vivo and in-vitro models. In-vivo studies involved an optic nerve crush rat model with intravitreal injections...

Inflammatory macular holes

The authors present a case of closure of a full thickness macular hole in a patient with Behçet’s disease, without surgery. The 23-year-old male they describe presented with a history of recurrent oral aphthous ulcers and a genital ulcer. Ocular...

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

Cytokine levels in vitreous fluid in patients with pathological myopia

Pathological myopia (PM) is a leading cause of irreversible visual impairment worldwide, and efforts are dedicated to the study of its underlying mechanisms. Axial extension of the eyeball is regulated via a cascade of biochemical molecules that are initiated in...

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...